Cetilistat

Description

What is Cetilistat?

Cetilistat is a novel inhibitor of pancreatic lipase being developed by Alizyme for the treatment of obesity and associated co-morbidities, including type 2 diabetes.

Cetilistat (also known as ATL-962) was approved in September 2013 by the Japanese Ministry of Health, Labor and Welfare for the treatment of obesity, limited to patients with both type 2 diabetes mellitus (T2DM) and dyslipidemia, and with a body mass index (BMI)25 kg/m² in spite of dietary treatment and/or exercise therapy.

Introduction

Product Name:	Cetilistat
Synonyms:	Citilistat; Cetilistat INN; Cametor
CAS:	282526-98-1
MF:	C25H39NO3
MW:	401.58
EINECS:	1308068-626-2
Product Categories:	API; Intermediates & Fine Chemicals; Pharmaceuticals

Structure

Cetilistat

Chemical Properties

Melting point	72.0 to 76.0 °C
Boiling point	509.7±43.0 °C(Predicted)
density	1.02
storage temp.	Sealed in dry,2-8°C
pka	2.96±0.20(Predicted)
InChIKey	MVCQKIKWYUURMU-UHFFFAOYSA-N

Cetilistat Uses And Synthesis

Cetilistat is a novel pancreatic lipase inhibitor for the treatment of obesity in both diabetic and non-diabetic patients. Cetilistat works via inhibition of pancreatic lipases in the gut to inhibit fat absorption and thereby reduce caloric uptake from diet.

Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

MSDS: MSDS available.

COA: COA can be available if you send us inquiry.

Email us at: info@maxmedchem.com for more details.